Reducing the burden of Herpes Zoster in Italy

Gabutti, Giovanni; Franco, Elisabetta; Bonanni, Paolo; Conversano, Michele; Ferro, António; Lazzari, Marzia; Maggi, Stefania; Rossi, Alessandro; Scotti, Silvestro; Vitale, Francesco; Volpi, Antonio; Greco, Donato

doi:10.4161/hv.34363

Cited by 15 publications

(13 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Herpes Zoster (HZ) is the clinical manifestation of reactivation of varicella-zoster virus remained latent in dorsal root or cranial nerve sensory ganglia after primary infection. It is a considerable cause of morbidity, especially in elderly, immunosuppressed, or critically ill patients [1]. In Europe, approximately 1.7 million new cases of HZ are expected each year with an incidence rate in adults aged 50 years and older, between 6 and 8 cases per 1000 person-years [2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

The Unknown Health Burden of Herpes Zoster Hospitalizations: The Effect on Chronic Disease Course in Adult Patients ≥50 Years

et al. 2020

View full text Add to dashboard Cite

The effect of severe Herpes Zoster (HZ) on chronic diseases is a component of the real burden of this vaccine-preventable disease that is not commonly considered. A retrospective cohort study was conducted to assess the health burden of severe HZ in adults ≥50 years residing in Liguria Region from 2015 to 2017. Subjects hospitalized with and without HZ were matched (1:6 ratio). 437 subjects in the HZ cohort and 2622 subjects in the non-HZ cohort were enrolled. Previous immunodeficiency, autoimmune, and rare diseases are identified as main chronic conditions related to HZ hospitalization. Higher incidences of autoimmune (1.4% vs. 0.22%, p = 0.002) and gastrointestinal (7.04% vs. 3.62%, p = 0.015) diseases after hospitalization were observed in the HZ cohort compared to the non-HZ cohort. Significantly higher incidences were found after hospitalization versus the previous period for cardiovascular diseases (11.17% vs. 2.09%, p < 0.001), cerebral vasculopathy (6.13% vs. 0.60%, p < 0.001), non-arrhythmic myocardiopathy (4.31% vs. 0.59%, p = 0.002), and neuropathy (2.62% vs. 0.56%, p = 0.033). The HZ cohort showed a relative risk 10-fold higher for cerebral vasculopathy, 5-fold higher for cardiovascular diseases, and 7-fold higher for non-arrhythmic myocardiopathy. HZ causes a substantial impact on the chronic conditions. These data could suggest an implementation of HZ vaccination programs in the elderly and in high-risk groups.

show abstract

Section: Introductionmentioning

confidence: 99%

The Unknown Health Burden of Herpes Zoster Hospitalizations: The Effect on Chronic Disease Course in Adult Patients ≥50 Years

et al. 2020

View full text Add to dashboard Cite

show abstract

“…As a whole, the impact of HZ in terms of morbidity and short- and long-term complications, the availability of suboptimal treatment options, and the high costs for the diagnostic and clinical therapeutic management of patients have motivated the search for a new preventive approach through the development of a vaccine. 13 …”

Section: Introductionmentioning

confidence: 99%

“… 31 ZVL is contraindicated in subjects with a history of hypersensitivity to any component of the vaccine, suffering from primitive or acquired immunodeficiency, on immunosuppressive therapy (including high doses of corticosteroids), with untreated active tuberculosis and pregnancy. 13 ZVL should be administered 14–30 days before the start of any immunosuppressive treatment. 31 , 32…”

Section: Introductionmentioning

confidence: 99%

A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile

Brosio¹,

Masetti²,

Matteo³

et al. 2018

IDR

Self Cite

View full text Add to dashboard Cite

Herpes zoster (HZ) is an acute vesicular dermatitis with a typical dermatomal distribution, caused by the varicella zoster virus (VZV), often preceded and accompanied by prodromal pain or pruritus. HZ may be related to several complications such as postherpetic neuralgia (PHN). The incidence and severity of the disease increase with aging, due to immunosenescence and in particular to the decline of the specific cell-mediated immunity (CMI). The impact of HZ in terms of morbidity and short- and long-term complications, the availability of suboptimal treatment options to date, and the high costs for the diagnostic and clinical-therapeutic management of patients have motivated the search for a new preventive approach through the development of a vaccine. The vaccine currently in use with live-attenuated virus (ZVL) has been shown to be effective in reducing the incidence of HZ, its impact, and the onset of PHN, although the efficacy is lower in older subjects and tends to decrease some years after immunization. A new adjuvanted recombinant subunit vaccine (HZ/su), containing the VZV glycoprotein E (gE) and the AS01B adjuvant system, is now a very promising alternative to ZVL; in several clinical studies, it showed a good safety profile and was able to elicit high immune humoral and cell-mediated responses, both maintained up to 9 years. Furthermore, HZ/su vaccine was effective both in preventing HZ and in reducing the onset of PHN and other complications. HZ/su has been recommended and preferred over ZVL by the Advisory Committee on Immunization Practices (ACIP) for the prevention of HZ and its complications in immunocompetent adults aged ≥50 years, even if already vaccinated with ZVL, through a two-dose schedule. HZ/su has been approved in Canada, USA, Europe, and Japan and is currently being approved in Australia. The aim of this review was to describe the epidemiological data, HZ and PHN risks and their impact on the social life and common life of infected people, and ZVL and HZ/su vaccine development including various clinical trials and efficacy, safety, and tolerability profiles.

show abstract

“…Including HZ vaccination in its citizens' lifetime immunization calendar can reinforce Europe's commitment toward active, healthy aging. This paper outlines the consensus statement of a group of Italian experts on HZ: particular emphasis is placed on the disease's burden on the country's senior citizens [5].…”

Section: Introductionmentioning

confidence: 99%

Preventing and managing herpes zoster: key actions to foster healthy aging

et al. 2015

Self Cite

View full text Add to dashboard Cite

Population aging is the demographic phenomenon characterizing all countries in the world, and it is challenging the national infrastructures, in particular health systems. However, aging itself is not associated with increased medical spending, but disability and comorbidity that affect older individuals are the actual drivers for health expenditures. Therefore, if people age in better health, medical spending may be significantly reduced. Preventative interventions proved to be effective in reducing/preventing disease and disability and often found to be cost effective, include diet and exercise interventions, medications, routine disease screenings, and immunizations. Vaccination can protect older citizens against life-threatening diseases, such as influenza, pneumococcal infections, tetanus, and against diseases which adversely impact their quality of life, such as herpes zoster (HZ). Including HZ vaccination in its citizens' lifetime immunization calendar can reinforce Europe's commitment toward active, healthy aging. This paper outlines the consensus statement of a group of Italian experts on HZ.

show abstract

Reducing the burden of Herpes Zoster in Italy

Cited by 15 publications

References 61 publications

The Unknown Health Burden of Herpes Zoster Hospitalizations: The Effect on Chronic Disease Course in Adult Patients ≥50 Years

The Unknown Health Burden of Herpes Zoster Hospitalizations: The Effect on Chronic Disease Course in Adult Patients ≥50 Years

A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile

Preventing and managing herpes zoster: key actions to foster healthy aging

Contact Info

Product

Resources

About